

Introducing the Science behind Targeted Treatments for non-small cell lung cancer and immunotherapy

Wednesday 2nd September 2020

Event ID: 845

Introduction: Over the course of two mornings, experienced cancer educator, Dr Elaine Vickers, guides you through many of the most relevant topics relating to modern systemic treatments for non-small cell lung cancer (NSCLC).

The first morning's focus is on the gene faults that drive many NSCLCs and on the targeted treatments that exploit these faults, such as inhibitors of EGFR, ALK, ROS1, B-Raf, HER2, MET and RET.

The second morning is about cancer's relationship with the immune system and on the checkpoint inhibitor group of immunotherapies, which include PD-1, PD-L1 and CTLA-4 targeted antibody therapies.

As ever, Elaine's presentations are full of colourful and enlightening illustrations to help learners make sense of scientific concepts. Elaine's descriptions avoid unnecessary jargon and are pitched so that even those with a limited understanding of cell biology are able to understand.

Format:

Each morning's content is split over three pre-recorded videos of 30-40 minutes each. Elaine will be online throughout both mornings to interact with learners and answer questions in the live Q&A sessions that follow each video.

Audience: This content is ideal for research nurses, clinical nurse specialists, pharmacists and clinical trials coordinators. It may also be of interest to other healthcare professionals involved in the diagnosis and treatment of people with lung cancer, and to junior doctors.

Cost: £50 per delegate

Register: www.royalmarsden.nhs.uk/studydays

Get in touch:  Conferenceteam@rmh.nhs.uk

 020 7808 2921

Follow us:



Please note that the content will be available for 30 days after the event online

Topic 1:

Introducing the science behind targeted treatments for non-small cell lung cancer

Description of content:

Over the course of three videos, experienced cancer educator, Dr Elaine Vickers, guides you through the gene faults and mutations that drive non-small lung cancer (NSCLC). She also explains the rationale behind a wide range of targeted treatments used in the treatment of this disease.

Session 1—Lung Cancer Biology and Genetics

- Cell of origin of lung cancer
- DNA Mutations that drive NSCLC
- The impact of smoking on NSCLC genetics
- The role of EGFR signalling in lung cancer cells

Live Q&A

Session 2—EGFR Inhibitors

- EGFR inhibitors—mechanisms of action
- Difference between reversible inhibitors (erlotinib, gefitinib) and irreversible inhibitors (dacomitinib, afatinib, osimertinib)
- Latest clinical trials data from 2020

Live Q&A

Session 3—other targets and treatments

- Targetable mutations other than EGFR
- ALK and ROS1 inhibitors
- Newer targets in NSCLC: MET, RET, BRAF, HER2, NTRK mutations
- Angiogenesis inhibitors

Live Q&A

Trailer Video: Introducing Immunotherapy for Lung Cancer

Main Sponsors:



The above sponsors provided funding for the study day, but they have had no input into the programme, selection of speakers or topics.